The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
Part of paid clinical trials in Pheonix, Arizona.
- Sponsor
- Aerpio Therapeutics
- Study ID
- NCT02050828
- Phase
- PHASE2
- Status
- Completed
Conditions
- Diabetic Macular Edema (DME)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- AKB-9778 — DRUG
- ranibizumab — DRUG
- Placebo — DRUG
- Sham — DRUG
Study Details
The purpose of this study is to evaluate the safety and efficacy of AKB-9778 administered as daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab for 3 months in patients with diabetic macular edema.
Key Dates
- First listed
- Jan 31, 2014
- Start date
- Jan 31, 2014
- Status verified
- Mar 2017
- Primary completion
- Apr 30, 2015
- Completion
- May 31, 2015
Study Design
- Enrollment
- 144 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: AKB-9778 15 mg BID monotherapySubcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
- Experimental: AKB-9778 15 mg BID + ranibizumab 0.3 mgSubcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
- Active Comparator: ranibizumab 0.3 mg monotherapyPlacebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
Primary Outcome Measure
Mean change from baseline in spectral domain optical coherence tomography (sdOCT)-measured central subfield thickness (CST) [ Time Frame: Month 3 ]
Locations (39)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Pheonix | Arizona | 85014 | - |
| - | Pheonix | Arizona | 85020 | - |
| - | Tucson | Arizona | 85704 | - |
| - | Arcadia | California | 91007 | - |
| - | Bakersfield | California | 93309 | - |
| - | Beverly Hills | California | 90211 | - |
| - | Palm Desert | California | 92260 | - |
| - | Sacramento | California | 95819 | - |
| - | Santa Ana | California | 92705 | - |
| - | Santa Barbara | California | 93103 | - |
| - | Golden | Colorado | 80401 | - |
| - | Boynton Beach | Florida | 33426 | - |
| - | Fort Lauderdale | Florida | 33334 | - |
| - | Fort Myers | Florida | 33912 | - |
| - | Miami | Florida | 33126 | - |
| - | Sarasota | Florida | 34239 | - |
| - | Stuart | Florida | 34994 | - |
| - | Winter Haven | Florida | 33880 | - |
| - | Baltimore | Maryland | 21287 | - |
| - | Jackson | Michigan | 49202 | - |
| - | Omaha | Nebraska | 68198 | - |
| - | Reno | Nevada | 89502 | - |
| - | Rochester | New York | 14620 | - |
| - | Charlotte | North Carolina | 28210 | - |
| - | Cincinnati | Ohio | 45242 | - |
| - | Cleveland | Ohio | 44195 | - |
| - | Portland | Oregon | 97210 | - |
| - | Florence | South Carolina | 29501 | - |
| - | Rapid City | South Dakota | 57701 | - |
| - | Nashville | Tennessee | 37203 | - |
| - | Abilene | Texas | 79606 | - |
| - | Austin | Texas | 78705 | - |
| - | Fort Worth | Texas | 76102 | - |
| - | Houston | Texas | 77030 | - |
| - | McAllen | Texas | 78503 | - |
| - | San Antonio | Texas | 78240 | - |
| - | Salt Lake City | Utah | 84107 | - |
| - | Warrenton | Virginia | 20186 | - |
| - | Bellevue | Washington | 98004 | - |
Related Studies
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyPHASE4 · Recruiting · Retina Consultants of Orange County · Fullerton, California
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Bakersfield, California
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPHASE4 · Enrolling By Invitation · Harrow Inc · Tyler, Texas